Valuation: MBX Biosciences, Inc.

Capitalization 1.6B 1.36B 1.25B 1.19B 2.2B 149B 2.24B 14.68B 5.76B 71.95B 6.02B 5.89B 254B P/E ratio 2026 *
-11.7x
P/E ratio 2027 * -9.13x
Enterprise value 1.49B 1.27B 1.16B 1.1B 2.04B 138B 2.08B 13.63B 5.34B 66.79B 5.59B 5.47B 236B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
96.76%
Yield 2026 *
-
Yield 2027 * -
1 day+1.66%
1 week+8.94%
Current month+13.13%
1 month+13.55%
3 months-16.68%
6 months+155.45%
Current year+7.07%
1 week 30.76
Extreme 30.76
35
1 month 26.14
Extreme 26.14
35
Current year 26.14
Extreme 26.14
44.89
1 year 7.2
Extreme 7.2
44.89
3 years 4.81
Extreme 4.8069
44.89
5 years 4.81
Extreme 4.8069
44.89
10 years 4.81
Extreme 4.8069
44.89
Manager TitleAgeSince
Chief Executive Officer 57 2019-12-31
Director of Finance/CFO 45 2022-03-31
Chief Tech/Sci/R&D Officer - 2023-12-31
Director TitleAgeSince
Chairman 57 2019-12-31
Director/Board Member 66 2020-06-30
Director/Board Member 55 2020-06-30
Change 5d. change 1-year change 3-years change Capi.($)
+1.66%+8.94%+343.18% - 1.6B
+2.22%+5.51%+0.78%-7.93% 48.69B
+0.99%+4.59%+40.22%+22.31% 35.92B
-0.43%+54.13%+304.33%+504.92% 31.26B
-0.72%+3.91%+35.55%+29.11% 29.77B
+2.62%+5.45%+22.62%-12.91% 29.62B
-6.22%-0.52%+3,641.35%+3,836.02% 14.18B
+0.63%+2.17%+48.12%+195.41% 15.1B
+0.96%+5.48%+75.71%+166.26% 14.87B
+0.87%+8.85%+40.89%+13.56% 14.5B
Average +0.26%+9.72%+455.28%+527.42% 23.55B
Weighted average by Cap. +0.58%+11.10%+285.94%+327.84%

Financials

2026 *2027 *
Net sales - -
Net income -137M -116M -107M -101M -187M -12.68B -191M -1.25B -491M -6.14B -514M -503M -21.71B -188M -160M -147M -139M -257M -17.39B -262M -1.72B -674M -8.42B -705M -690M -29.79B
Net Debt -115M -97.91M -89.95M -85.21M -158M -10.66B -161M -1.05B -413M -5.16B -432M -423M -18.26B -153M -130M -119M -113M -209M -14.15B -213M -1.4B -548M -6.85B -573M -561M -24.24B
Logo MBX Biosciences, Inc.
MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. It has built its proprietary Precision Endocrine Peptide platform to develop precision peptide therapies that are designed to overcome key limitations of current peptide therapies. Its product candidates and programs include MBX 2109, MBX 1416 and Obesity portfolio. MBX 2109 is a parathyroid hormone peptide prodrug that is designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism. MBX 1416 is designed to be a long-acting glucagon-like peptide-1 (GLP-1), receptor antagonist, as a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. MBX 4291 is designed to be a long-acting and highly potent GLP-1 and glucose-dependent insulinotropic polypeptide, receptor co-agonist prodrug.
Employees
63
Date Price Change Volume
26-04-17 33.77 $ +1.66% 306,798
26-04-16 33.22 $ +0.79% 217,048
26-04-15 32.96 $ +0.46% 317,865
26-04-14 32.81 $ 0.00% 462,163
26-04-13 32.81 $ +5.84% 300,132
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
33.77USD
Average target price
62.55USD
Spread / Average Target
+85.21%

Quarterly revenue - Rate of surprise